References
- Dunkelberger JR , SongWC. Complement and its role in innate and adaptive immune responses. Cell Res. 20 (1), 34–50 (2010).
- Rother RP , RollinsSA, MojcikCF, BrodskyRA, BellL. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25 (11), 1256–1264 (2007).
- Hillmen P , YoungNS, SchubertJet al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355 (12), 1233–1243 (2006).
- Legendre CM , LichtC, MuusPet al. Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N. Engl. J. Med. 368 (23), 2169–2181 (2013).
- EMA . Eculizumab. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000791/WC500054208.pdf.
- US FDA . Eculizumab label information. www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf.
- Gatault P , BrachetG, TernantDet al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs7 (6), 1205–1211 (2015).
- Jodele S , FukudaT, MizunoKet al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 22 (2), 307–315 (2016).
- Peffault de Latour R , Fremeaux-BacchiV, PorcherRet al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood125 (5), 775–783 (2015).
- Noris M , GalbuseraM, GastoldiSet al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood124 (11), 1715–1726 (2014).
- Hillmen P , HallC, MarshJCWet al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350 (6), 552–559 (2004).
- Guideline on Bioanalytical Method Validation . European Medicines Agency, London, UK (2011).
- Guidance for Industry Bioanalytical Method Validation . US FDA, MD, USA (2001).
- DeSilva B , SmithW, WeinerRet al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20 (11), 1885–900 (2003).
- Viswanathan CT , BansalS, BoothBet al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24 (10), 1962–1973 (2007).
- Bilić-Zulle L . Comparison of methods: passing and bablok regression. Biochem. Med. 21 (1), 49–52 (2011).
- Smolec J , DeSilvaB, SmithWet al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 22 (9), 1425–1431 (2005).